Advertisement

2012 ASH Annual Meeting

supportive care

Fixed-dose Apixaban Reduces Risk of Recurrent Venous Thromboembolism

Venous thromboembolism is a frequent problem in cancer patients, and approximately 20% of all patients who develop the disease have a recurrence. Extending treatment with two fixed doses of the invest...

hematologic malignancies

Umbilical Cord Blood Transplant: Two Units are No Better Than One in Children with Hematologic Malignancies

Use of two partially HLA-matched units of umbilical cord blood were not superior to a single unit if it contained an adequate number of hematopoietic stem cells, according to a randomized study by the...

leukemia

Excellent Preliminary Results for Ibrutinib in Chronic Lymphocytic Leukemia

Although still in preliminary testing with no phase III data, ibrutinib is poised to become an important new agent for patients with chronic lymphocytic leukemia (CLL). Two phase II trials reported at...

multiple myeloma

Oral Proteasome Inhibitor May Be a Game-changer in Myeloma

An investigational oral proteasome inhibitor currently known as MLN9708 could make the treatment of multiple myeloma much more convenient and possibly less neurotoxic, according to the results of a ph...

multiple myeloma

Overall Survival Benefit Achieved with Pomalidomide in Advanced Myeloma

Support for the oral immunomodulatory agent pomalidomide for multiple myeloma took a step forward when the phase III MM-003 trial showed a survival advantage in patients with advanced disease, in addi...

hematologic malignancies
leukemia

Pivotal Trial Shows Robust Activity of Ponatinib in Some Heavily Pretreated Leukemias

The pivotal phase II Ponatinib Ph+ ALL and CML Evaluation (PACE trial) found that 1 year of treatment with the novel investigational drug ponatinib achieved robust activity in heavily pretreated patie...

lymphoma

PET-negative Scan after Short-course Chemotherapy Identifies Early Hodgkin Lymphoma Patients Who Can Forgo Radiation

Positron-emission tomography (PET)-directed therapy is promising for early-stage Hodgkin lymphoma, according to results of the UK NCRI RAPID trial presented at the 54th Annual Meeting of the American ...

leukemia

Inotuzumab Moves Forward in Relapsed/Refractory ALL 

Single-agent inotuzumab ozogamicin achieved an encouraging overall response rate of 57% in the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL) in a phase II trial reported at the 5...

lymphoma

Ibrutinib in Mantle Cell Lymphoma Yields 'Unprecedented' Response Rates 

The investigational agent ibrutinib demonstrated “unprecedented” single-agent activity in relapsed or refractory mantle cell lymphoma, according to the lead author of an international phase II study r...

multiple myeloma

Survival Benefit Achieved with Four Drugs plus Maintenance in Myeloma

An overall survival benefit in newly diagnosed multiple myeloma was attained with a four-drug induction regimen followed by a duet for maintenance in a study from the Italian GIMEMA network. Antonio P...

leukemia
lymphoma
multiple myeloma

ASH Highlights Included New Data in Myeloma, Lymphoma, and Leukemia, plus Studies of Mucositis and Graft-vs-Host Disease

The 54th Annual Meeting of the American Society of Hematology (ASH) featured about 5,000 abstracts, including oral sessions and posters, as well as named lectures and symposia. In addition to our regu...

leukemia

Daunorubicin-free Induction Therapy for Standard-risk Childhood Acute Lymphoblastic Leukemia 

Omitting daunorubicin from induction therapy for children with standard-risk acute B-cell lymphoblastic leukemia (ALL) does not compromise survival and at the same time reduces the risk of associated ...

leukemia

Expert Point of View: Farhad Ravandi, MD 

Over the past 2 decades, we have witnessed remarkable progress in the treatment of patients with acute promyelocytic leukemia (APL). The introduction of all-trans retinoic acid (ATRA) in the front-lin...

leukemia

Chemotherapy-free Regimen Successful in Acute Promyelocytic Leukemia 

For the first time, a chemotherapy-free regimen was superior to conventional cytotoxic chemotherapy for the treatment of acute promyelocytic leukemia (APL). The combination of all-trans retinoic acid ...

leukemia
lymphoma
multiple myeloma

More Brief Reports from ASH, Including New Data in Leukemia, Lymphoma, and Myelodysplastic Syndrome

At the 54th Annual Meeting of the American Society of Hematology (ASH), held in Atlanta, nearly 5,000 abstracts were presented in oral sessions and posters. As part of our ongoing comprehensive covera...

hematologic malignancies

No Rationale for Eliminating Prophylactic Platelet Transfusions in Patients with Hematologic Malignancies 

Prophylactic platelet transfusions should remain the standard of care for many patients with hematologic malignancies who are thrombocytopenic during intensive treatment or stem cell transplant, inves...

hematologic malignancies
multiple myeloma

High Infection Rates Found in Multiple Myeloma Patients, With High Mortality  

A large Swedish study using population-based data to estimate the risk of bacterial and viral infections among 9,610 patients with multiple myeloma (9,253 eligible for analysis) found that the myeloma...

lymphoma

Cytarabine in Conditioning Regimen for Younger Patients with MCL 

High-dose cytarabine should be incorporated into the induction regimen of younger patients with mantle cell lymphoma (MCL) before autologous stem cell transplantation, according to final results of th...

hematologic malignancies
leukemia
issues in oncology

Quizartinib Data Encouraging in Phase II Investigations of FLT3 Mutation–positive Acute Myeloid Leukemia

The investigational oral FLT3 inhibitor quizartinib appears to be a safe and effective treatment for patients with relapsed or refractory acute myeloid leukemia (AML), according to results of a phase ...

hematologic malignancies
lymphoma

Bendamustine/Rituximab Noninferior to Standard Chemotherapy for Advanced Indolent Non-Hodgkin and Mantle Cell Lymphomas 

The combination of bendamustine (Treanda) and rituximab (Rituxan), or BR, was found to be noninferior to commonly used chemotherapy with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristi...

Advertisement

Advertisement



Advertisement

click me